Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025Blood ScienceOpen Access

CD7 CAR-T therapy: current developments, improvements, and dilemmas

View Full Paper
Ask AI
Bookmark
Share

Authors

LWL.H. WangSQShaowei Qiu

Discussion

Loading...

Member takes

Overview

Review discusses cd7 car-t therapy's applications in t-cell leukemia and approaches to overcome graft-versus-host disease.

Key Points

  • CD7 CAR-T therapy shows promise in treating relapsed T-cell acute lymphoblastic leukemia and acute myeloid leukemia.
  • Allogeneic CD7 CAR-T cells potentially reduce manufacturing costs and improve availability compared to autologous cells.
  • New gene-editing techniques like CRISPR/Cas9 are being explored to address challenges in CD7 CAR-T therapy.
  • The review examines current applications and future directions for refining CD7 CAR-T products in clinical settings.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d18bfhttps://doi.org/10.1097/bs9.0000000000000247
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies.2024
  2. 2CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
  3. 3Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation2024 · 4 citations
  4. 4Have CARs stalled for non–B-cell malignancies? Where are we, and where are we going?2025 · 1 citations
  5. 5Efficacy, Safety, and Kinetics of Naturally Selected Anti‐ CD7 CAR ‐T Cell Therapy in T‐ ALL / LBL With CNS Leukemia2026